Clinical trials
Chronic Liver Disease clinical trials
Below are recruiting chronic liver disease clinical trials, each written for real people, not researchers. We’re tracking 399 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05554224Recruiting
Personalized treatment based on obesity-related fatty liver tests
This study uses multiple types of health data (“multi-omics”) to help choose a personalized treatment plan for people with obesity-related fatty liver disease. It may help match treatment to your biology to improve outcomes.
Reus, TarragonaAges 18 years+ - NCT06836609RecruitingPhase 1/Phase 2
Study of a new drug for fatty liver disease (MASLD/MASH)
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
Chandler, ArizonaAges 18–65 - NCT07652151Recruiting
Fatty Liver Disease Study Using Wearable Tracking
This research studies fatty liver disease linked to metabolic problems like diabetes and obesity. You'll wear a fitness tracker and have liver imaging to help doctors understand the disease and find new treatments.
RomaAges 18 years+ - NCT07603817Recruiting
Thyroid Disease and Fatty Liver Disease Study
This study looks at the connection between thyroid problems (especially when the thyroid doesn't make enough hormone) and a common liver condition where fat builds up in the liver. Researchers want to understand how these two conditions relate to each other in people without diabetes.
Sohag, Sohag GovernorateAges 18 years+ - NCT07355868RecruitingEarly Phase 1
Cell therapy for COPD
This trial is testing a new type of cell therapy called REGEND007 for people with COPD. It looks at whether the treatment can help improve how far you can walk and your overall breathing.
Yiwu, ZhejiangAges 40–80 - NCT06152250Recruiting
Fatty liver inflammation study with liver biopsy
This study looks at how the liver's immune environment changes in people with non-alcoholic fatty liver disease (NAFLD) that has progressed to significant scarring. Researchers will use a liver biopsy to understand the inflammation better, which may lead to new treatments.
Lyon, Auvergne-Rhône-AlpesAges 18 years+ - NCT07494409RecruitingPhase 3
A new oral medicine for anemia in dialysis patients
This trial tests a new oral medicine (AND017) for people on dialysis who have anemia (low red blood cells). It may help reduce the need for injections of standard anemia medicines.
ShanghaiAges 18–75 - NCT07619157RecruitingPhase 1
ONO-3310 Study for Kidney Disease and Type 2 Diabetes
This early-stage trial tests a new drug called ONO-3310 in two groups: healthy adults and people with kidney disease caused by type 2 diabetes. The study aims to understand how the drug works and whether it might help protect kidney function in people with diabetes.
Fukuoka, FukuokaAges 18–64 - NCT07238985RecruitingPhase 1/Phase 2
Cilostazol for treating nonalcoholic fatty liver disease
This study tests whether a medicine called cilostazol can help treat nonalcoholic fatty liver disease. It is for adults who have fatty liver seen on an ultrasound and do not have other liver problems.
Damietta, New DamiettaAges 18–60 - NCT07242222RecruitingPhase 1/Phase 2
Erdosteine for non-alcoholic fatty liver disease
This trial tests whether a medicine called erdosteine can help treat non-alcoholic fatty liver disease (a condition where extra fat builds up in the liver, not caused by alcohol). It is for adults who have fatty liver confirmed by ultrasound and who do not have other serious health problems.
TantaAges 18–60 - NCT07662889Enrolling by invitation
Comparing two types of dialysis for kidney failure
This trial compares a newer type of dialysis called hemodiafiltration with standard hemodialysis to see if it improves certain health measures in people with end-stage kidney disease. It may help determine which method works better for long-term treatment.
Lahore, Punjab ProvinceAges 18–70 - NCT06165341RecruitingPhase 3
Fazirsiran for mild liver scarring in alpha-1 antitrypsin deficiency
This study tests an investigational drug called fazirsiran, which is designed to treat alpha-1 antitrypsin deficiency-related liver disease with mild scarring. The goal is to see if fazirsiran is safe and can improve or slow liver damage in people with the PiZZ genetic type.
Phoenix, ArizonaAges 18–75 - NCT06824974Recruiting
Time-restricted eating for liver disease or cancer
This study tests whether combining time-restricted eating with healthy eating helps people with metabolic liver disease, cirrhosis, or early-stage liver cancer. If you are overweight and currently fast less than 12 hours at night, this diet approach might improve your health.
La Jolla, CaliforniaAges 18 years+ - NCT06883578Recruiting
Effect of a low valine diet on body weight and metabolism
This trial studies if a diet low in valine, a building block of protein, can help people with excess weight lose weight and improve their metabolic health. It may offer an alternative approach for weight loss.
Shanghai, Shanghai MunicipalityAges 16–80 - NCT07646197Recruiting
Peanut Consumption and Fatty Liver Disease in Adults
This study tests whether eating peanuts regularly can help improve fatty liver disease (a condition where fat builds up in the liver). You'll be asked to eat peanuts as part of your diet while researchers track changes in your liver health.
Detroit, MichiganAges 30–70 - NCT05689645RecruitingPhase 2
Drug trial for liver injury or liver failure
This Phase 2 trial tests an injection medicine (F573) to see if it can improve people with liver injury, drug-related liver damage, or liver failure. You may be screened with blood tests, liver stiffness measurements, and possibly symptom checks.
Beijing, Beijing MunicipalityAges 18–60 - NCT06438445Recruiting
Royal Jelly Supplement for Kidney Disease on Dialysis
This study tests whether a daily supplement called royal jelly can help people with chronic kidney disease who are on dialysis. Researchers will check if it improves health markers.
Rio de Janeiro, Rio de JaneiroAges 18–70 - NCT04944615Recruiting
IVUS-guided stent placement for blocked heart artery using longer guidance
This trial compares two ways to place a stent (a small mesh tube) for a completely blocked heart artery: using an IVUS camera inside the artery versus using a standard x-ray approach. It may help people get better heart outcomes by improving how accurately the stent is placed in long-term blockages.
BeijingAges 18 years+ - NCT07534241Recruiting
Reishi Mushroom for Fatty Liver Disease
This study tests whether reishi mushroom (a type of fungus) can improve liver health in people with metabolic dysfunction-associated fatty liver disease—a condition where fat builds up in the liver. Researchers want to see if this natural supplement can reduce liver inflammation and improve blood sugar and cholesterol levels.
LahoreAges 35–65 - NCT07610837RecruitingPhase 2
Testing AZD2389 for fatty liver disease with scarring
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
Chandler, ArizonaAges 18 years+ - NCT06206616Recruiting
Liver fat in children with celiac disease
This study looks at whether children with celiac disease have fat buildup in the liver. It aims to help doctors understand and manage this condition better.
Palermo, PalermoAges 1–14 - NCT07750535Recruiting
Liver fat and scarring in wheat-sensitive patients
This study looks at whether people with non-celiac wheat sensitivity or other digestive conditions have more fat in their liver or liver scarring. It aims to understand if wheat-related issues are linked to liver health.
Palermo, PalermoAges 18–65 - NCT06632600RecruitingPhase 2
Study of LXE408 for people with chronic Chagas disease
This trial tests a new drug called LXE408 for people with chronic Chagas disease. It aims to see if the drug is safe and effective, and participants will also receive standard treatment with benznidazole.
Sylmar, CaliforniaAges 18–60 - NCT06402851RecruitingPhase 4
Blood thinner or none for atrial fibrillation with dialysis
This trial compares two types of blood thinners (vitamin K antagonists and factor Xa inhibitors) versus no blood thinner in people with atrial fibrillation who are on dialysis or have very advanced kidney disease. It aims to see which option is safest and most effective for preventing strokes and bleeds.
Salvador, Estado de BahiaAges 18 years+
Hear when a new Chronic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic liver disease?
- Yes. Clin2 currently lists 399 recruiting chronic liver disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic liver disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic liver disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.